Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Trickey, Adam ^a   May, Margaret T ^a   Vehreschild, Janne ^b,c,aa   Obel, Niels ^d   Gill, Michael John ^e,ai   Crane, Heidi ^f   Boesecke, Christoph ^g   Samji, Hasina ^h,i   Grabar, Sophie ^j,k,l   Cazanave, Charles ^m   Cavassini, Matthias ^n,ac   Shepherd, Leah ^o,an   Monforte, Antonella D'Arminio ^p,af   Smit, Colette ^q,ao   Saag, Michael ^r   Lampe, Fiona ^o   Hernando, Vicky ^s   Montero, Marta ^t   Zangerle, Robert ^u   Justice, Amy C ^v,w,am   Sterling, Timothy ^x,ap   Miro, Jose ^y,ab   Ingle, Suzanne ^a   Sterne, Jonathan A C ^a   Boulle, Andrew ^z   Stephan, Christoph ^aa   Chêne, Geneviève ^ad   Costagliola, Dominique ^ae   Dabis, François ^ad   Del Amo, Julia ^ag   Van Sighem, Ard ^ah   Guest, Jodie ^aj   Haerry, David Hans Ulrich ^ak   Hogg, Robert ^al   McRane, Heidi ^aa   Reiss, Peter ^ah   Teira, Ramon ^aq   Williams, Matthew ^ar   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d Copenhagen University Hospital ^*  (Denmark)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF BONN   (Germany)

^h BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

ⁱ SIMON FRASER UNIVERSITY   (Canada)

^j SORBONNE UNIVERSITÉ   (France)

^k INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^l université Paris Cité   (France)

^m HÔPITAL PELLEGRIN   (France)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^o ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^p UNIVERSITY OF MILAN   (Italy)

^q STICHTING HIV MONITORING   (Netherlands)

^r and Clinical Center   (United States)

^s CARLOS III INSTITUTE OF HEALTH   (Spain)

^t HOSPITAL UNIVERSITARIO LA FE   (Spain)

^u INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^v YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^w VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^x VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y UNIVERSITY OF BARCELONA   (Spain)

^z IeDEA Southern Africa   (Spain)

^aa SHCS ^*  (United States)

^ab PISCIS   (Spain)

^ac SHCS   (Spain)

^ad Aquitaine   (France)

^ae FHDH   (France)

^af ICONA   (Sweden)

^ag HAVACS ^*  (United States)

^ah ATHENA   (United States)

^ai South Alberta Clinic   (France)

^aj HAVACS   (United Kingdom)

^ak EUROPEAN AIDS TREATMENT GROUP   (Belgium)

^al HOMER   (Greece)

^am VACS   (India)

^an EuroSIDA   (Netherlands)

^ao Sheila Sherlock Liver Center   (United Kingdom)

^ap NONE   (United States)

^aq VACH   (Germany)

^ar UK COMMUNITY ADVISORY BOARD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MORTALITY RISK; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION; AGED; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MORTALITY; PHYSIOLOGY; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DEMOGRAPHY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84986579099     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160460     Document Type: Article

References (46)

1. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001; 15(11):1369-77. PMID: 11504958
2. Blanco JL, Whitlock G, Milinkovic A, Moyle G. HIV integrase inhibitors: a new era in the treatment of HIV. Expert opinion on pharmacotherapy. 2015; 16(9):1313-24. doi: 10.1517/14656566.2015.1044436 PMID: 26001181
3. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013; 27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0 PMID: 23343913
4. Astuti N, Maggiolo F. Single-Tablet Regimens in HIV Therapy. Infectious diseases and therapy. 2014; 3(1):1-17. doi: 10.1007/s40121-014-0024-z PMID: 25134808
5. The Antiretroviral Therapy Cohort C. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010; 50 (10):1387-96. doi: 10.1086/652283 PMID: 20380565
6. Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014; 59(2):287-97. doi: 10.1093/cid/ciu261 PMID: 24771333
7. Lima V, Lourenço L, Yip B, Hogg B, Phillips P, Montaner J. Trends in AIDS incidence and AIDS-related mortality in British Columbia between 1981 and 2013. Lancet HIV. 2015; 2(3):92-7.
8. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014; 384 (9939):241-8. doi: 10.1016/S0140-6736(14)60604-8 PMID: 25042234
9. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360(9327):119-29. PMID: 12126821
10. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007; 21(9):1185-97. PMID: 17502729
11. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011; 22 (4):516-23. doi: 10.1097/EDE.0b013e31821b5332 PMID: 21522013
12. Ehren K, Hertenstein C, Kummerle T, Vehreschild JJ, Fischer J, Gillor D, et al. Causes of death in HIVinfected patients from the Cologne-Bonn cohort. Infection. 2014; 42(1):135-40. doi: 10.1007/s15010-013-0535-7 PMID: 24081925
13. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, et al. All-cause mortality in treated HIV-infected adults with CD4 >/= 500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. International journal of epidemiology. 2012; 41 (2):433-45. doi: 10.1093/ije/dyr164 PMID: 22493325
14. Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011; 6(7):e22698. doi: 10.1371/journal.pone.0022698 PMID: 21799935
15. Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009; 23(16):2199-208. doi: 10.1097/QAD.0b013e3283305a00 PMID: 19779320
16. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). IJE. 2013: 12.
17. Kowalska JD, Kirk O, Mocroft A, Hoj L, Friis-Moller N, Reiss P, et al. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV Med. 2010; 11(3):200-8. doi: 10.1111/j.1468-1293.2009.00763.x PMID: 19863618
18. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). Journal of Acquired Immune Deficiency Syndromes. 2008; 48(5):590-8. doi: 10.1097/QAI.0b013e31817efb54 PMID: 18645512
19. May M, Porter K, Sterne JA, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. Journal of clinical epidemiology. 2005; 58(10):1033-41. PMID: 16168349
20. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002; 21(15):2175-97. PMID: 12210632
21. Fine J, Gray R. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association. 1999; 94(446):496-509.
22. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013; 27(4):563-72. doi: 10.1097/QAD.0b013e32835b8c7f PMID: 23095314
23. May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International journal of epidemiology. 2012; 41(6):1807-20. doi: 10.1093/ije/dys164 PMID: 23148105
24. Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection. 2011; 39 (1):13-20. doi: 10.1007/s15010-010-0079-z PMID: 21246246
25. Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS medicine. 2012; 9(3):e1001194. doi: 10.1371/journal. pmed.1001194 PMID: 22448150
26. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007; 46(1):72-7. PMID: 17621240
27. McManus H, O'Connor CC, Boyd M, Broom J, Russell D, Watson K, et al. Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One. 2012; 7(11):e48839. doi: 10.1371/journal.pone.0048839 PMID: 23144991
28. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014; 28 (8):1193-202. doi: 10.1097/QAD.0000000000000243 PMID: 24556869
29. Legarth RA, Ahlstrom MG, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Long-Term Mortality in HIV-Infected Individuals 50 Years or Older: A Nationwide, Population-Based Cohort Study. J Acquir Immune Defic Syndr. 2016; 71(2):213-8. doi: 10.1097/QAI.0000000000000825 PMID: 26334734
30. Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer screening in patients infected with HIV. Current HIV/AIDS reports. 2011; 8(3):142-52. doi: 10.1007/s11904-011-0085-5 PMID: 21695529
31. Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43(1):27-34. PMID: 16878047
32. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012; 26(3):315-23. doi: 10.1097/QAD. 0b013e32834e8805 PMID: 22112597
33. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, et al. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV clinical trials. 2011; 12(2):109-17. doi: 10.1310/hct1202-109 PMID: 21498154
34. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008; 22(16):2143-53. doi: 10.1097/QAD.0b013e3283112b77 PMID: 18832878
35. Data Collection on Adverse Events of Anti HIVdSG, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010; 24(10):1537-48. doi: 10.1097/QAD.0b013e32833a0918 PMID: 20453631
36. Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, et al. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection. 2014; 42(4):757-62. doi: 10.1007/s15010-014-0630-4 PMID: 24902520
37. Wells JS, Holstad MM, Thomas T, Bruner DW. An integrative review of guidelines for anal cancer screening in HIV-infected persons. AIDS patient care and STDs. 2014; 28(7):350-7. doi: 10.1089/apc. 2013.0358 PMID: 24936878
38. Laut KG, Mocroft A, Lazarus J, Reiss P, Rockstroh J, Karpov I, et al. Regional differences in selfreported HIV care and management in the EuroSIDA study. J Int AIDS Soc. 2014; 17(4 Suppl 3):19504. doi: 10.7448/IAS.17.4.19504 PMID: 25394013
39. Thorsteinsson K, Ladelund S, Jensen-Fangel S, Katzenstein TL, Johansen IS, Pedersen G, et al. Adherence to the cervical cancer screening program in women living with HIV in Denmark: comparison with the general population. BMC Infect Dis. 2014; 14:256. doi: 10.1186/1471-2334-14-256 PMID: 24885577
40. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians. 2012; 62(4):220-41.
41. Kim HW, Song KS, Goo JM, Lee JS, Lee KS, Lim TH. Thoracic Sequelae and Complications of Tuberculosis. RadioGraphics. 2001; 21:839-60. PMID: 11452057
42. Swain SD, Han S, Harmsen A, Shampeny K, Harmsen AG. Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia. The American journal of pathology. 2007; 171(3):790-9. PMID: 17640969
43. May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, et al. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr. 2015; 69(3):348-54. doi: 10.1097/QAI.0000000000000603 PMID: 25848927
44. Weber R, Huber M, Battegay M, Stahelin C, Castro Batanjer E, Calmy A, et al. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV Med. 2015; 16(3):137-51. doi: 10.1111/hiv.12184 PMID: 25124393
45. Weber R, Huber M, Rickenbach M, Furrer H, Elzi L, Hirschel B, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med. 2009; 10(7):407-16. doi: 10.1111/j.1468-1293.2009.00701.x PMID: 19490174
46. Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013; 8(2):e55312. doi: 10.1371/journal.pone.0055312 PMID: 23457467